Compare DAR & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAR | PTGX |
|---|---|---|
| Founded | 1882 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.4B |
| IPO Year | 1994 | 2016 |
| Metric | DAR | PTGX |
|---|---|---|
| Price | $36.47 | $89.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | $44.75 | ★ $86.44 |
| AVG Volume (30 Days) | ★ 2.2M | 898.7K |
| Earning Date | 10-23-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.67 | ★ 0.72 |
| Revenue | ★ $5,843,771,000.00 | $209,217,000.00 |
| Revenue This Year | $5.26 | N/A |
| Revenue Next Year | $4.67 | $296.47 |
| P/E Ratio | ★ $54.21 | $124.48 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.00 | $33.70 |
| 52 Week High | $42.15 | $93.25 |
| Indicator | DAR | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 62.33 | 64.67 |
| Support Level | $36.10 | $83.52 |
| Resistance Level | $37.87 | $90.85 |
| Average True Range (ATR) | 1.39 | 2.63 |
| MACD | 0.16 | -0.33 |
| Stochastic Oscillator | 76.80 | 83.62 |
Darling Ingredients Inc develops and manufactures sustainable ingredients for customers in the pharmaceutical, food, pet food, fuel, and fertilizer industries. It collects and transforms all aspects of animal by-product streams into ingredients, including gelatin, fats, proteins, pet food ingredients, fertilizers. Also, the company recovers and converts used cooking oil and bakery remnants into feed and fuel ingredients. Darling has three primary business segments which are feed ingredients contributing the majority of revenue, food ingredients, and fuel ingredients. It provides grease trap services for food businesses and sells various equipment for collecting and delivering cooking oil. The company derives the majority of its revenue from customers in North America.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.